InflaRx NV
(NASDAQ : IFRX)

( )
IFRX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
IMMUImmunomedics, Inc. -0.26%85.0311.0%$728.04m
MRNAModerna, Inc. 0.33%70.750.0%$670.05m
AMGNAmgen, Inc. 2.36%254.161.3%$669.90m
ILMNIllumina, Inc. 1.17%309.083.5%$646.09m
NVAXNovavax, Inc. 0.37%108.3596.5%$600.09m
GILDGilead Sciences, Inc. 1.76%63.191.0%$591.39m
REGNRegeneron Pharmaceuticals, Inc. -2.41%559.782.7%$463.31m
VRTXVertex Pharmaceuticals, Inc. 0.67%272.121.9%$349.26m
BIIBBiogen, Inc. 0.47%283.681.6%$346.64m
SRNESorrento Therapeutics, Inc. -3.88%11.151.4%$316.35m
EXASEXACT Sciences Corp. -0.06%101.9520.7%$266.37m
ALXNAlexion Pharmaceuticals, Inc. 1.75%114.432.0%$262.90m
SGENSeattle Genetics, Inc. 2.48%195.696.0%$235.67m
VXRTVaxart, Inc. -2.56%6.650.0%$191.96m
MNTAMomenta Pharmaceuticals, Inc. -0.02%52.483.0%$191.71m

Company Profile

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products include IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.